移植前细胞减少治疗对接受同种异体造血干细胞移植的MDS或MDS继发性AML患者预后的影响：一项随机对照试验的二次分析

IF 12.9 1区医学 Q1 HEMATOLOGY

Blood Cancer Journal Pub Date : 2025-02-19 DOI:10.1038/s41408-025-01233-9

Rongtao Xue, Min Dai, Erlie Jiang, Xueying Ou, Fen Huang, Zhiping Fan, Na Xu, Chenhua Yan, Danian Nie, Xinquan Liang, Hong Chen, Jieyu Ye, Ling Jiang, Hui Liu, Hua Jin, Ren Lin, Yu Zhang, Jing Sun, Mingzhe Han, Qifa Liu, Yu Wang, Li Xuan

{"title":"移植前细胞减少治疗对接受同种异体造血干细胞移植的MDS或MDS继发性AML患者预后的影响：一项随机对照试验的二次分析","authors":"Rongtao Xue, Min Dai, Erlie Jiang, Xueying Ou, Fen Huang, Zhiping Fan, Na Xu, Chenhua Yan, Danian Nie, Xinquan Liang, Hong Chen, Jieyu Ye, Ling Jiang, Hui Liu, Hua Jin, Ren Lin, Yu Zhang, Jing Sun, Mingzhe Han, Qifa Liu, Yu Wang, Li Xuan","doi":"10.1038/s41408-025-01233-9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"51 1","pages":""},"PeriodicalIF":12.9000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT\",\"authors\":\"Rongtao Xue, Min Dai, Erlie Jiang, Xueying Ou, Fen Huang, Zhiping Fan, Na Xu, Chenhua Yan, Danian Nie, Xinquan Liang, Hong Chen, Jieyu Ye, Ling Jiang, Hui Liu, Hua Jin, Ren Lin, Yu Zhang, Jing Sun, Mingzhe Han, Qifa Liu, Yu Wang, Li Xuan\",\"doi\":\"10.1038/s41408-025-01233-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8989,\"journal\":{\"name\":\"Blood Cancer Journal\",\"volume\":\"51 1\",\"pages\":\"\"},\"PeriodicalIF\":12.9000,\"publicationDate\":\"2025-02-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41408-025-01233-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-025-01233-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT

查看原文本刊更多论文

Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood Cancer Journal ONCOLOGY-

CiteScore

16.70

自引率

2.30%

发文量

153

审稿时长

>12 weeks

期刊介绍： Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.